{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:29:00Z","timestamp":1770971340172,"version":"3.50.1"},"reference-count":31,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Febrile neutropenia is a prevalent oncologic complication. Initiating rapid treatment\nwith empirical antimicrobials in febrile neutropenia patients reduces mortality due to infections.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>The study aims to evaluate antimicrobial utilization among FN patients in Lebanon in\nterms of drug choice, dose, and duration of the treatment. This is a retrospective, multicenter, observational\nstudy conducted at three different Lebanese university hospitals (in which the Infectious\nDiseases Society of America (IDSA) guidelines are adopted), between February 2014 and\nMay 2017.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Setting:<\/jats:title>\n<jats:p>This is a retrospective, multicenter, observational study was conducted at three different Lebanese university hospitals (in which the Infectious Diseases Society of America (IDSA) guidelines are adopted), between February 2014 and May 2017.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Adult cancer patients aged 18 years and older with febrile neutropenia were included in\nthe study. Using the IDSA guidelines as a reference, patients were assessed whether they received\nthe antimicrobial regimen inconsistent with the IDSA reference or not. Statistical analysis was performed\nusing the Statistical Package for the Social Science software (SPSS version 22.0).\nThe adherence to guidelines for the indication and doses of antibiotics and anti-fungal in patients\nwith febrile neutropenia.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>A total of 124 patients with a mean age of 54.43 \u00b1 17.86 years were enrolled in the study.\nLeukemia (29.7%) was the most prevalent cancer and the most common infection was sepsis\n(20.2%). Combination antibiotic lactams are the most prescribed antibiotics (86.8%). Only 94\n(86.23%) patients were given the antibiotic therapy appropriate for choice, dose, and duration.\nEmpirical antifungal therapy was initiated in 63.7% of the patients and fluconazole was the most\nused antifungal (36.3%). In contrast to antibiotics, the majority of antifungal choices were not selected\naccording to the recommendations and they were considered inappropriate for doses and the\nrequired treatment duration as proposed by (IDSA). Fifty-eight percent of patients received antivirals,\neven though it is not recommended as empirical treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>In conclusion, this study reveals a non-consistent antimicrobial utilization practice at\nthe involved sites concerning FN treatment. Inappropriateness was encountered in drug selection,\ndose, and duration of treatment with antifungals and antivirals.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574886317666220620153115","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T06:44:23Z","timestamp":1655793863000},"page":"496-503","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessment of Antimicrobial Utilization among Cancer Patients with\nFebrile Neutropenia at the Lebanese Hospitals"],"prefix":"10.2174","volume":"18","author":[{"given":"Sarah","family":"Cherri","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Lebanese International University, Mouseitbah, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Malaeb","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Lebanese International University, Mouseitbah, Beirut, Lebanon"},{"name":"College of Pharmacy, Gulf Medical University, Ajman, United Arab Emirates."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamis","family":"Shouman","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Lebanese International University, Mouseitbah, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iqbal","family":"Fahs","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Lebanese International University, Mouseitbah, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabih","family":"Hallit","sequence":"additional","affiliation":[{"name":"School of Medicine and Medical Sciences, Holy Spirit University of Kaslik, Jounieh, Lebanon"},{"name":"Department of Infectious Disease, Bellevue Medical Center, Mansourieh, Lebanon"},{"name":"Department of Infectious Disease,\nNotre Dame des Secours, University Hospital Center, Byblos, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souheil","family":"Hallit","sequence":"additional","affiliation":[{"name":"School of Medicine and Medical Sciences, Holy Spirit University of Kaslik, Jounieh, Lebanon"},{"name":"Psychology Department, College of Humanities, Effat University, Jeddah, 21478, Saudi Arabia."},{"name":"Research Department, Psychiatric Hospital of the Cross, Jal Eddib, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassem","family":"Malaeb","sequence":"additional","affiliation":[{"name":"Dr. Sulaiman Al-Habib Medical Group, Dubai, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Salameh","sequence":"additional","affiliation":[{"name":"INSPECT-LB: Institut National de Sant\u00e9 Publique, \u00c9pid\u00e9miologie Clinique et Toxicologie, Beirut, Lebanon"},{"name":"School of Medicine, Lebanese American University, Byblos, Lebanon"},{"name":"Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus"},{"name":"Faculty of Pharmacy, Lebanese University, Hadat, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1097\/CCM.0b013e3181cc4824","volume":"38","author":"Gaieski D.F.","year":"2010","unstructured":"Gaieski D.F.; Mikkelsen M.E.; Band R.A.; Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010,38(4),1045-1053","journal-title":"Crit Care Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"S240","DOI":"10.1086\/427329","volume":"40","author":"Viscoli C.","year":"2005","unstructured":"Viscoli C.; Varnier O.; Machetti M.; Infections in patients with febrile neutropenia: Epidemiology, microbiology, and risk stratification. Clin Infect Dis 2005,40(Suppl. 4),S240-S245","journal-title":"Clin Infect Dis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1086\/383050","volume":"39","author":"Klastersky J.","year":"2004","unstructured":"Klastersky J.; Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 2004,39(Suppl. 1),S32-S37","journal-title":"Clin Infect Dis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/cid\/ciq147","volume":"52","author":"Freifeld A.G.","year":"2011","unstructured":"Freifeld A.G.; Bow E.J.; Sepkowitz K.A.; Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the infectious diseases society of america. Clin Infect Dis 2011,52(4),427-431","journal-title":"Clin Infect Dis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1086\/374339","volume":"36","author":"Wisplinghoff H.","year":"2003","unstructured":"Wisplinghoff H.; Seifert H.; Wenzel R.P.; Edmond M.B.; Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003,36(9),1103-1110","journal-title":"Clin Infect Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1200\/JOP.091092","volume":"6","author":"Lyman G.H.","year":"2010","unstructured":"Lyman G.H.; Rolston K.V.; How we treat febrile neutropenia in patients receiving cancer chemotherapy. J Oncol Pract 2010,6(3),149-152","journal-title":"J Oncol Pract"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4067\/S0716-10182019000200167","volume":"36","author":"Santolaya M.E.","year":"2019","unstructured":"Santolaya M.E.; &#xC1;lvarez A.M.; Bidart T.; Morales J.; Gonz&#xE1;lez C.; Antimicrobial therapy in cancer patients and hematopoietic stem cell transplantation receptors. Rev Chilena Infectol 2019,36(2),167-178","journal-title":"Rev Chilena Infectol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"878","DOI":"10.15537\/smj.2018.9.22824","volume":"39","author":"Calik S.","year":"2018","unstructured":"Calik S.; Ari A.; Bilgir O.; The relationship between mortality and microbiological parameters in febrile neutropenic patients with hematological malignancies. Saudi Med J 2018,39(9),878-885","journal-title":"Saudi Med J"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1086\/505393","volume":"43","author":"Bow E.J.","year":"2006","unstructured":"Bow E.J.; Rotstein C.; Noskin G.A.; A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 2006,43(4),447-459","journal-title":"Clin Infect Dis"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1469-0691.2005.01239.x","volume":"11","author":"Glasmacher A.","year":"2005","unstructured":"Glasmacher A.; von Lilienfeld-Toal M.; Schulte S.; Hahn C.; Schmidt-Wolf I.G.; Prentice A.; An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect 2005,11(Suppl. 5),17-23","journal-title":"Clin Microbiol Infect"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/00365540410017590","volume":"36","author":"Cherif H.","year":"2004","unstructured":"Cherif H.; Bj&#xF6;rkholm M.; Engervall P.; A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis 2004,36(8),593-600","journal-title":"Scand J Infect Dis"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1200\/JCO.2000.18.5.1012","volume":"18","author":"Klaassen R.J.","year":"2000","unstructured":"Klaassen R.J.; Goodman T.R.; Pham B.; Doyle J.J.; &#x201C;Low-risk&#x201D; prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000,18(5),1012-1019","journal-title":"J Clin Oncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"CD003992","DOI":"10.1002\/14651858.CD003992.pub3","volume":"2016","author":"Vidal L.","year":"2013","unstructured":"Vidal L.; Ben Dor I.; Paul M.; Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 2013,2016(10),CD003992","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1086\/510393","volume":"44","author":"Dellit T.H.","year":"2007","unstructured":"Dellit T.H.; Owens R.C.; McGowan J.E.; Infectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007,44(2),159-177","journal-title":"Clin Infect Dis"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.apjtb.2015.09.014","volume":"5","author":"G&#xF6;r&#xFC;k M.","year":"2015","unstructured":"G&#xF6;r&#xFC;k M.; Dal M.; Dal T.; Evaluation of febrile neutropenic patients hospitalized in a hematology clinic. Asian Pac J Trop Biomed 2015,5(12),1051-1054","journal-title":"Asian Pac J Trop Biomed"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/sj.bjc.6606059","volume":"104","author":"Okera M.","year":"2011","unstructured":"Okera M.; Chan S.; Dernede U.; A prospective study of chemotherapy-induced febrile neutropenia in the South West London cancer network. Interpretation of study results in light of NCAG\/NCEPOD findings. Br J Cancer 2011,104(3),407-412","journal-title":"Br J Cancer"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/2049936113475610","volume":"1","author":"Alp S.","year":"2013","unstructured":"Alp S.; Akova M.; Management of febrile neutropenia in the era of bacterial resistance. Ther Adv Infect Dis 2013,1(1),37-43","journal-title":"Ther Adv Infect Dis"},{"key":"ref=18","first-page":"136","volume":"48","author":"Hamzeh F.","year":"2000","unstructured":"Hamzeh F.; Kanj S.S.; Uwaydah M.; Febrile neutropenia in cancer patients in a tertiary care medical center in Lebanon: Microbial spectrum and outcome. J Med Liban 2000,48(3),136-142","journal-title":"J Med Liban"},{"key":"ref=19","first-page":"6","volume":"8","author":"Kanj S.S.","year":"2001","unstructured":"Kanj S.S.; Adel N.; Araj G.F.; The continued prevalence of Gram-negative infections in febrile neutropenic patients in Lebanon. Comparison with studies from the Middle East. BMJ 2001,8,6-13","journal-title":"BMJ"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ijid.2006.12.008","volume":"11","author":"Kanafani Z.A.","year":"2007","unstructured":"Kanafani Z.A.; Dakdouki G.K.; El-Chammas K.I.; Eid S.; Araj G.F.; Kanj S.S.; Bloodstream infections in febrile neutropenic patients at a tertiary care center in Lebanon: A view of the past decade. Int J Infect Dis 2007,11(5),450-453","journal-title":"Int J Infect Dis"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"S386","DOI":"10.1016\/j.clml.2017.07.236","volume":"17","author":"Sakr R.","year":"2017","unstructured":"Sakr R.; Massoud M.; Greige W.; Outcome of neutropenic fever in hospitalized cancer patients during a one-year follow-up: A single center experience. Clin Lymphoma Myeloma Leuk 2017,17,S386","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1086\/339215","volume":"34","author":"Hughes W.T.","year":"2002","unstructured":"Hughes W.T.; Armstrong D.; Bodey G.P.; 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002,34(6),730-751","journal-title":"Clin Infect Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"Kuderer N.M.","year":"2006","unstructured":"Kuderer N.M.; Dale D.C.; Crawford J.; Cosler L.E.; Lyman G.H.; Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006,106(10),2258-2266","journal-title":"Cancer"},{"key":"ref=24","first-page":"776","volume":"93","author":"Roongpoovapatr P.","year":"2010","unstructured":"Roongpoovapatr P.; Suankratay C.; Causative pathogens of fever in neutropenic patients at King Chulalongkorn Memorial Hospital. J Med Assoc Thai 2010,93(7),776-783","journal-title":"J Med Assoc Thai"},{"key":"ref=25","year":"2017","unstructured":"United States Cancer StatisticsAvailable from:  (Accessed on June 6, 2022).2017"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/oby.22137","volume":"26","author":"Berger N.A.","year":"2018","unstructured":"Berger N.A.; Young adult cancer: Influence of the obesity pandemic. Obesity 2018,26(4),641-650","journal-title":"Obesity"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ebiom.2018.02.022","volume":"30","author":"Stone T.W.","year":"2018","unstructured":"Stone T.W.; McPherson M.; Gail Darlington L.; Obesity and cancer: Existing and new hypotheses for a causal connection. EBioMedicine 2018,30,14-28","journal-title":"EBioMedicine"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1155\/2013\/291546","volume":"2013","author":"De Pergola G.","year":"2013","unstructured":"De Pergola G.; Silvestris F.; Obesity as a major risk factor for cancer. J Obes 2013,2013,11","journal-title":"J Obes"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1634\/theoncologist.2010-0206","volume":"15","author":"Lichtman M.A.","year":"2010","unstructured":"Lichtman M.A.; Obesity and the risk for a hematological malignancy: Leukemia, lymphoma, or myeloma. Oncologist 2010,15(10),1083-1101","journal-title":"Oncologist"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5581\/1516-8484.20130009","volume":"35","author":"Lima S.S.","year":"2013","unstructured":"Lima S.S.; Fran&#xE7;a M.S.; Godoi C.C.; Neutropenic patients and their infectious complications at a University Hospital. Rev Bras Hematol Hemoter 2013,35(1),18-22","journal-title":"Rev Bras Hematol Hemoter"},{"key":"ref=31","first-page":"55","volume":"26","author":"Billote K.P.","year":"1997","unstructured":"Billote K.P.; Mendoza M.Y.; Baylon H.G.; Infections in febrile neutropenia and possible prognostic factors associated with mortality. Philipp J Microbiol Infect Dis 1997,26(2),55-59","journal-title":"Philipp J Microbiol Infect Dis"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886317666220620153115","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/206217\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886317666220620153115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T12:09:35Z","timestamp":1691323775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/206217\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886317666220620153115","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-01-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}